Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | OGA | O60502 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17039215 | 0.79 | GRM5 (0.54) | GRM5OGABACE1ACACB | |
| SCHEMBL29471995 | 0.79 | BACE1 (0.40) | GRM5BACE1ACACB | |
| SCHEMBL22531721 | 0.79 | BACE1 (0.40) | GRM5BACE1ACACB | |
| SCHEMBL3958689 | 0.78 | CCR1 (0.43) | GRM5 | |
| SCHEMBL1914210 | 0.78 | GRM5 (0.39) | GRM5 | |
| SCHEMBL1137069 | 0.76 | ADRA2A (0.37) | GRM5BACE1 | |
| SCHEMBL19453039 | 0.76 | HCAR2 (0.34) | GRM5 | |
| SCHEMBL3212577 | 0.76 | ADRA2A (0.36) | GRM5 | |
| SCHEMBL29350657 | 0.76 | ADRA2A (0.37) | GRM5BACE1 | |
| SCHEMBL8973225 | 0.76 | ADRA2A (0.36) | GRM5BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116171280-A | Casein kinase 1 delta modulators | 詹森药业有限公司 | 2023-05-26 | — | — | CN | disclosed |
| CN-109563120-B | alpha-D-galactoside inhibitors of galectins | 格莱克特生物技术公司 | 2022-12-02 | — | — | CN | disclosed |
| US-10988502-B2 | Alpha-D-galactoside inhibitors of galectins | GALECTO BIOTECH AB (DK) | 2021-04-27 | — | — | US | disclosed |
| CN-112566636-A | Compound and use thereof | 优曼尼蒂治疗公司 | 2021-03-26 | — | — | CN | disclosed |
| US-10919885-B2 | Compounds and uses thereof | YUMANITY THERAPEUTICS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190330198-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-31 | — | — | US | disclosed |
| US-20190225638-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2019-07-25 | — | — | US | disclosed |
| WO-2010063487-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919885-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | GRM5 68/4885OGA 3313/4885BACE1 31/4885 |
| US-20190330198-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | GRM5 68/4885OGA 3313/4885BACE1 31/4885 |
| US-20190225638-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | LGALS1, LGALS2, LGALS3 | GRM5 1669/4885OGA 297/4885BACE1 465/4885 |
| US-10988502-B2 | Alpha-D-galactoside inhibitors of galectins | LGALS1, LGALS2, LGALS3 | GRM5 1669/4885OGA 297/4885BACE1 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.